Uncategorized

There have already been several big biotech licensing deals in Q1. See inside for some of this quarter’s biggest licensing deals — from the surprising and pivotal to the lucrative and consequential.

Insurance and provider lobbies called on the CMS to delay the rule earlier this month, saying the methodology was flawed and arguing the 30-day comment period didn’t give them enough time to analyze the proposed changes.

Citing reports of “alarming toxicity” among other accusations, short-seller Scorpion Capital will file a Citizen’s Petition with the FDA to have its approval of Wakix withdrawn.

Boston-based Covant Therapeutics gained $10 million upfront in a deal with Boehringer Ingelheim to chase after a cancer immunotherapy target, ADAR1.

Amazon Pharmacy is currently offering coupons for eight brand name medications treating diabetes, asthma, obesity, emphysema and others, and said it plans to add more coupons over time.

The company, which reported a net loss on Tuesday, is also exploring strategic alternatives for its Xoft therapy business.

The FDA could decline premarket submissions that lack adequate cybersecurity information.

The groups argue the expansion of the FCA would threaten the “legitimate business activities of every government contractor, hospital, healthcare provider, health insurance provider, and grant recipient in the nation.”

Expenses were still high in February, though rising prices for goods and services were more to blame than costly labor, according to the report.

Tuesday, Viking Therapeutics released Phase I results for its weight-loss candidate VK2735, which demonstrated a good safety and tolerability profile and resulted in significant weight reductions.